Details of the Drug Formulations

General Information of Drug (ID: DMBD4K3)

• Drug Name: Selinexor Drug Info
• Synonyms: Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]
Liposarcoma	2B59	Phase 3	[2]
Neuroendocrine cancer	2B72.1	Phase 3	[2]
Acute myeloid leukaemia	2A60	Phase 2	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Diffuse large B-cell lymphoma	2A81	Phase 2	[3]
Recurrent glioblastoma	2A00.00	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]

• Cross-matching ID:
  PubChem CID: 71481097
  CAS Number: 1393477-72-9
  TTD ID: D00LNW
  INTEDE ID: DR1472
  ACDINA ID: D01420

Full List of Drug Formulations Containing This Drug

Selinexor 20mg tablet

Company	Formulation ID	FDA Description
Karyopharm Therapeutics	F23285	Colloidal Silicon Dioxide; Croscarmellose Sodium; Magnesium Stearate; Microcrystalline Cellulose; Opadry 200 Clear; Opadry Ii Blue; Povidone K30; Sodium Lauryl Sulfate

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT04349098) Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02025985) Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies. U.S. National Institutes of Health.